KRYS Jumps As Analysts Race To Lift Price Targets

Krystal Biotech Inc. stocks have been trading up by 5.91 percent following highly positive coverage of its gene-therapy pipeline.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading KRYS

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

BofA raised its price target on Krystal Biotech to $396 from $364 while reiterating a Buy rating, reflecting stronger long-term expectations for Vyjuvek ex-U.S. and increased confidence in KB801 for neurotrophic keratitis, despite slightly lower 2026 estimates.
Jefferies raised its price target on Krystal Biotech from $399 to $474 while reiterating a Buy rating, citing expectations for another strong Q2 driven by sustained U.S. demand and increasing international revenue contribution.
TD Cowen raised Krystal Biotech’s price target to $403 from $306 and reiterated a Buy rating, citing significant expected value from its pipeline, including de-risked Phase 3 ‘801 NK data and promising early data for ‘407 in cystic fibrosis, with key readouts expected by year-end 2026.
Recent weekly action shows KRYS reclaiming the $350–$360 zone after a dip, backed by a strong intraday rebound from near $335 to the mid-$350s.

Weekly Update Jul 13 – Jul 17, 2026: On Saturday, July 18, 2026 Krystal Biotech Inc. stock [NASDAQ: KRYS] is trending up by 5.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Krystal Biotech (KRYS) now operates as a profitable, late‑commercial rare‑disease gene therapy company with best‑in‑class fundamentals versus biotech peers. Q1 2026 revenue of $116.4M annualizes to ~30% of FY revenue, with gross margin at an exceptional 94.2% and EBIT margin above 40%, validating pricing power and operating leverage. Balance sheet strength is outstanding: current ratio 9.5, negligible leverage (debt/equity 0.01), and $823M in cash and investments. ROE near 20% and free cash flow of ~$73M this quarter support the premium 35x P/E and ~18.5x sales.

Weekly trading data show a volatile but intact uptrend, with price rebounding from a brief dip near $338 to close at $362, signaling aggressive dip‑buying near that zone. Recent 5‑minute action shows elevated intraday volume and tight spreads, confirming strong liquidity and institutional participation. Dominant trend is higher with constructive pullbacks. A key actionable level is $338–$340 as primary support; as long as price holds above this band on closing basis, risk‑reward favors long positioning targeting a retest and break of recent highs.

More Breaking News

Fundamentally and sentiment‑wise, KRYS screens superior to broader Healthcare and Biotechnology & Life Sciences indices, which remain dominated by loss‑making names and weaker balance sheets. Multiple Buy‑rated target hikes (BofA to $396, Jefferies to $474, TD Cowen to $403) underscore rising conviction in Vyjuvek’s ex‑U.S. ramp and de‑risked KB801/KB407 pipeline. Near‑term resistance is $395–$400; support sits at $338 and then ~$320. Twelve‑month risk‑adjusted fair value is $410–$430 with clear upside skew.

Quick Financial Overview

Krystal Biotech Inc. is trading in the mid-$300s after a volatile but constructive week. The weekly data show price trading as low as $338 and as high as $363, with the most recent close near $362. That puts KRYS back above the key $350 area after briefly undercutting it, a classic shakeout-and-reclaim pattern that often attracts momentum traders. The intraday five-minute candle confirms this, with price ripping from roughly $335 to about $355 in a single session, signaling strong dip demand.

On the fundamentals, Krystal Biotech Inc. printed quarterly revenue of about $116.4M and trailing revenue near $389.1M, with a gross margin above 94%. Operating income of roughly $53.7M and an EBIT margin around 41% show that the current product base, led by Vyjuvek, is already throwing off real operating profits. A profit margin above 50% and a P/E near 35.1 tell traders they are dealing with a high-expectation growth name, not a cheap value play.

Balance-sheet strength backs that premium. The company holds about $823.4M in cash and short-term investments and only minimal long-term debt, with a current ratio around 9.5 and total debt-to-equity near 0.01. Operating cash flow of about $80.4M and free cash flow of roughly $73.2M in the latest quarter support the valuation and give Krystal Biotech Inc. firepower to fund its pipeline. For traders, that combination of high margins, positive cash flow, and a clean balance sheet reduces financing risk around the late-stage programs analysts are now baking into their targets.

Conclusion

Krystal Biotech Inc. now has a clear bullish narrative lining up across news, numbers, and tape. Three major firms — BofA, Jefferies, and TD Cowen — all raised price targets between $396 and $474 in 2026/07, while keeping Buy ratings. The drivers are consistent: strong current Vyjuvek demand, growing ex-U.S. expectations, and de-risked pipeline assets like KB801 for neurotrophic keratitis and the ‘407 program in cystic fibrosis. For traders, that means the story is no longer just one drug; it is a platform with a pipeline that the Street is actively repricing.

On the chart, KRYS has defended the mid-$330s and snapped back toward $360, with intraday action showing aggressive buying on dips. With a P/E above 35 and price-to-sales near 18.5, any stumble in Q2 or pipeline readouts could hit the stock hard, so risk needs to be sized accordingly. But as long as price holds above the recent $335–$340 low zone, the reward skew favors the upside continuation case backed by repeated target hikes. As I tell my students, “When price, earnings power, and fresh catalysts all point in the same direction, you do not chase blindly — you plan levels, define risk, and let the market pay you for being prepared.” That’s where disciplined execution matters. As Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.” This analysis is for educational and research purposes only.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!